PMID- 34902113
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220602
IS  - 2198-6576 (Print)
IS  - 2198-6584 (Electronic)
IS  - 2198-6576 (Linking)
VI  - 9
IP  - 2
DP  - 2022 Apr
TI  - Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in 
      Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
PG  - 313-329
LID - 10.1007/s40744-021-00409-6 [doi]
AB  - INTRODUCTION: Rheumatoid arthritis (RA) is a chronic debilitating illness, 
      usually associated with mental health ailments. Literature reports contradictory 
      observations about the association between recent RA pharmacotherapies and mental 
      health. We systematically reviewed RA randomized control trials to synthesize the 
      association between Janus kinases (JAK) inhibitors therapy and mental health. 
      METHODS: We systematically searched clinical trials of JAK inhibitor intervention 
      reporting mental health outcomes using short form-36 (SF-36) in PubMed, Embase, 
      and Scopus databases from inception to February 2021. We have selected the 
      studies and extracted the data, adhering to Preferred Reporting Items of 
      Systematic reviews and Meta-Analysis (PRISMA) guidelines. We have pooled the mean 
      change of SF-36 mental component score (MCS) between JAK inhibitors and 
      comparator therapy with a 95% confidence interval. RESULTS: Of the 2915 searched 
      studies for systematic review, 19 studies involving 14,323 individuals were 
      included for the meta-analysis. The pooled mean reduction in SF-36 MCS scores 
      (after minus before) with JAK inhibitors was 4.95 (4.41-5.48). The pooled mean 
      difference of incremental mean change in SF-36 MCS score between JAK monotherapy 
      and comparator was 1.53 (0.88-2.18). The improvement in SF-36 MCS scores with JAK 
      inhibitor therapy is greater than the minimum clinically important difference 
      (MCID) value of 2.5. However, on separate analysis with comparator drugs like 
      methotrexate and standard treatment, the MCS scores did not exceeded the MCID 
      value and were also not statistically significant. CONCLUSIONS: JAK inhibitors 
      results in clinically meaningful improvement in the mental health scores of the 
      RA patients. PROSPERO REGISTRATION ID: 2021 CRD42021234466.
CI  - (c) 2021. The Author(s).
FAU - Shamail, Ghazala M H
AU  - Shamail GMH
AD  - ICMR-National Institute of Epidemiology, Chennai, India.
FAU - Haridoss, Madhumitha
AU  - Haridoss M
AD  - Health Technology Assessment Resource Centre, ICMR-National Institute of 
      Epidemiology, R-127, Tamil Nadu Housing Board, Phase I and II, Ayapakkam, 
      Chennai, 600077, India.
FAU - Natarajan, Meenakumari
AU  - Natarajan M
AD  - Health Technology Assessment Resource Centre, ICMR-National Institute of 
      Epidemiology, R-127, Tamil Nadu Housing Board, Phase I and II, Ayapakkam, 
      Chennai, 600077, India.
FAU - Joshua, Vasna
AU  - Joshua V
AD  - ICMR-National Institute of Epidemiology, Chennai, India.
FAU - Bagepally, Bhavani Shankara
AU  - Bagepally BS
AUID- ORCID: 0000-0003-0856-767X
AD  - ICMR-National Institute of Epidemiology, Chennai, India. bagepally.bs@gov.in.
AD  - Health Technology Assessment Resource Centre, ICMR-National Institute of 
      Epidemiology, R-127, Tamil Nadu Housing Board, Phase I and II, Ayapakkam, 
      Chennai, 600077, India. bagepally.bs@gov.in.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211213
PL  - England
TA  - Rheumatol Ther
JT  - Rheumatology and therapy
JID - 101674543
PMC - PMC8964882
OTO - NOTNLM
OT  - Baricitinib
OT  - Filgotinib
OT  - Janus kinase inhibitors
OT  - Mental health
OT  - Rheumatoid arthritis
OT  - Short form-36
OT  - Tofacitinib
OT  - Upadacitinib
EDAT- 2021/12/14 06:00
MHDA- 2021/12/14 06:01
PMCR- 2021/12/13
CRDT- 2021/12/13 18:27
PHST- 2021/10/04 00:00 [received]
PHST- 2021/11/24 00:00 [accepted]
PHST- 2021/12/14 06:00 [pubmed]
PHST- 2021/12/14 06:01 [medline]
PHST- 2021/12/13 18:27 [entrez]
PHST- 2021/12/13 00:00 [pmc-release]
AID - 10.1007/s40744-021-00409-6 [pii]
AID - 409 [pii]
AID - 10.1007/s40744-021-00409-6 [doi]
PST - ppublish
SO  - Rheumatol Ther. 2022 Apr;9(2):313-329. doi: 10.1007/s40744-021-00409-6. Epub 2021 
      Dec 13.